SMC November Update
The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Quetiapine fumarate (Seroquel XL®) has been accepted for use in the the treatment of schizophrenia and manic episodes associated with bipolar disorder based on similar or lower costs compared to immediate-release quetiapine.
Insulin glulisine (Apidra®) has been restricted to use in the treatment of adolescents and children, 6 years or older with diabetes mellitus, where treatment with insulin is required and for whom soluble human insulin is inappropriate. This medicine has previously accepted with the same restrictions for use in adults.
Insulin lispro (Humalog KwikPen®, Mix25 KwikPen®, Mix50 KwikPen®) have all been accepted (KwikPen, Mix 25 and 50) for the treatment of patients with diabetes mellitus who require insulin for maintenance of normal glucose homeostasis, for whom either a short-acting insulin analogue or a biphasic insulin analogue is appropriate.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « Is lower cholesterol better? - The SEARCH continues | Systematic Review of IBS treatments » |
